Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

Phase 1CompletedNCT06101927

Tomsk National Research Medical Center of the Russian Academy of Sciences10 enrolled

Overview

The study should evaluate the biological distribution of \[99mTc\]Tc-BQ0413 in patients with prostate cancer. The primary objective are: 1. To assess the distribution of \[99mTc\]Tc- BQ0413 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc- BQ0413. 3. To study the safety and tolerability of the drug \[99mTc\]Tc- BQ0413 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[99mTc\]Tc- BQ0413 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer patients.

The overall goal is to study the effectiveness of SPECT imaging prostate cancer patients Using technetium-99m labeled BQ0413. Phase I of the study: Biodistribution of \[99mTc\]Tc-BQ0413 in patients with prostate cancer. The main objectives of the study: 1. To evaluate the distribution of \[99mTc\]Tc-BQ0413 in normal tissues and tumors in patients with prostate cancer at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc-BQ0413 based on the pharmacokinetic parameters of the drug after a single intravenous administration. 3. To study the safety of use and tolerability of the drug \[99mTc\]Tc-BQ0413 after a single intravenous administration in a diagnostic dosage. Additional research tasks: 1\. To conduct a comparative analysis of the diagnostic information obtained in the visualization of prostate cancer by SPECT using \[99mTc\]Tc-BQ0413 with data obtained by CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) research of postoperative material. Methodology: Open-label, exploratory, single centre study. The subjects will receive a single injection of the labeled tracer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

SINGLE

Enrollment

Eligibility

Sex: MALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is \> 18 years of age * Clinical and radiological diagnosis of prostate cancer with histological verification. * White blood cell count: \> 2.0 x 10\^9/L * Haemoglobin: \> 80 g/L * Platelets: \> 50.0 x 10\^9/L * Bilirubin =\< 2.0 times Upper Limit of Normal * Serum creatinine: Within Normal Limits * Blood glucose level not more than 5.9 mmol/L * Subject is capable to undergo the diagnostic investigations to be performed in the study * Informed consent Exclusion Criteria: * Active current autoimmune disease or history of autoimmune disease * Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) * Known HIV positive or chronically active hepatitis B or C * Administration of other investigational medicinal product within 30 days of screening * Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's

Outcomes

Primary Outcomes

Gamma camera-based whole-body [99mTc]Tc-BQ0413 uptake value (%)

Whole-body \[99mTc\]Tc-BQ0413 uptake coinciding with normal organs and tissues will be assessed using gamma camera and calculated as percentage (%) of the injected dose of the radiopharmaceutical

Time frame: 24 hours

SPECT-based [99mTc]Tc-BQ0413 value in tumor lesions (counts)

\[99mTc\]Tc-BQ0413 uptake coinciding with tumor lesions will be assessed using single-photon emission computed tomography and measured in counts

Time frame: 6 hours

SPECT-based [99mTc]Tc-BQ0413 uptake value (counts)

Focal uptake of \[99mTc\]Tc-BQ0413 in the regions without pathological findings will be assessed with SPECT and measured in counts

Time frame: 6 hours

Tumor-to-background ratio (SPECT)

The SPECT-based tumor-to-background ratio will be calculated as follows: the value of \[99mTc\]Tc-BQ0413 uptake coinciding with tumor lesions (counts) will be divided by the value of \[99mTc\]Tc-BQ0413 uptake coinciding with the regions without pathological findings (counts)

Time frame: 6 hours

Secondary Outcomes

Percent of cases with abnormal findings relative to baseline [Safety and Tolerability]

The safety attributable to \[99mTc\]Tc-BQ0413 injections will be evaluated based on the assessments of physical examination, vital signs, and ECG (percent of cases with abnormal findings relative to baseline)

Time frame: 24 hours

Percent of participants with abnormal laboratory values that are related to diagnostic imaging procedure [Safety and Tolerability]

The safety attributable to \[99mTc\]Tc-BQ0413 injections will be evaluated based on the blood and urine laboratory tests (percent of cases with abnormal findings relative to baseline)

Time frame: 24 hours

Percent of participants with adverse events that are related to diagnostic imaging procedure [Safety and Tolerability]

The safety attributable to \[99mTc\]Tc-BQ0413 injections will be evaluated based on the rate of adverse events (percent)

Time frame: 24 hours

Percent of participants requiring administration of medication due to side effects that are related to diagnostic imaging procedure [Safety and Tolerability]

The safety attributable to \[99mTc\]Tc-BQ0413 injections will be evaluated based on the rate of administration of concomitant medication (percent)

Time frame: 24 hours

Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes